AKT1 and Proteus syndrome: Furthermore, six Proteus syndrome patients were treated with 5 mg/m2/day of miransertib (1/7th oncologic dose) in a pilot study, which was well tolerated and achieved the primary endpoint of a 50% reduction in the tissue levels of AKT phosphorylation from biopsies in 5/6 affected individuals, as well as a decrease in a cerebriform connective tissue nevus and a reduction in pain in children [246].